Do analysts prefer XBIO or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend XBIO or AIXC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend XBIO or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VTGN or XBIO?

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 58.33%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe VistaGen Therapeutics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CPHI or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Xenetic Biosciences (XBIO) Competitors

$2.87 -0.03 (-1.03%)

As of 02:12 PM Eastern

Compare

XBIO vs. TAOX, AIXC, BCTX, VTGN, and CPHI

Should you buy Xenetic Biosciences stock or one of its competitors? MarketBeat compares Xenetic Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenetic Biosciences include Synaptogenix (TAOX), Qualigen Therapeutics (AIXC), Briacell Therap (BCTX), VistaGen Therapeutics (VTGN), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry.

How does Xenetic Biosciences compare to Synaptogenix?

Xenetic Biosciences (NASDAQ:XBIO) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Xenetic Biosciences' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Synaptogenix	Neutral

Synaptogenix has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Synaptogenix	N/A	-163.40%	-133.47%

Xenetic Biosciences has higher revenue and earnings than Synaptogenix. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.21	-$2.68M	-$1.20	N/A
Synaptogenix	$300K	85.06	-$28.74M	-$13.28	N/A

Summary

Xenetic Biosciences beats Synaptogenix on 8 of the 11 factors compared between the two stocks.

How does Xenetic Biosciences compare to Qualigen Therapeutics?

Xenetic Biosciences (NASDAQ:XBIO) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xenetic Biosciences has higher revenue and earnings than Qualigen Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.21	-$2.68M	-$1.20	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

In the previous week, Qualigen Therapeutics had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Qualigen Therapeutics	Neutral

Qualigen Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenetic Biosciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Xenetic Biosciences beats Qualigen Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Xenetic Biosciences compare to Briacell Therap?

Xenetic Biosciences (NASDAQ:XBIO) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Briacell Therap has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Briacell Therap	N/A	-153.53%	-129.26%

Xenetic Biosciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Briacell Therap had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 1 mentions for Briacell Therap and 0 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Briacell Therap	Neutral

Xenetic Biosciences has higher revenue and earnings than Briacell Therap. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.21	-$2.68M	-$1.20	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Summary

Xenetic Biosciences beats Briacell Therap on 7 of the 11 factors compared between the two stocks.

How does Xenetic Biosciences compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Xenetic Biosciences has higher revenue and earnings than VistaGen Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	19.38	-$69.68M	-$1.83	N/A
Xenetic Biosciences	$2.98M	2.21	-$2.68M	-$1.20	N/A

VistaGen Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

Xenetic Biosciences has a net margin of -70.03% compared to VistaGen Therapeutics' net margin of -5,487.01%. Xenetic Biosciences' return on equity of -39.28% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 1 mentions for VistaGen Therapeutics and 0 mentions for Xenetic Biosciences. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Xenetic Biosciences'average media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Xenetic Biosciences	Neutral

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 58.33%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe VistaGen Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Xenetic Biosciences beats VistaGen Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Xenetic Biosciences compare to China Pharma?

China Pharma (NYSE:CPHI) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Xenetic Biosciences has a net margin of -70.03% compared to China Pharma's net margin of -85.56%. Xenetic Biosciences' return on equity of -39.28% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

In the previous week, China Pharma had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 2 mentions for China Pharma and 0 mentions for Xenetic Biosciences. China Pharma's average media sentiment score of 0.15 beat Xenetic Biosciences' score of 0.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Neutral
Xenetic Biosciences	Neutral

15.1% of Xenetic Biosciences shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xenetic Biosciences has lower revenue, but higher earnings than China Pharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.03	-$3.08M	-$0.55	N/A
Xenetic Biosciences	$2.98M	2.21	-$2.68M	-$1.20	N/A

China Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

China Pharma and Xenetic Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIO vs. The Competition

Export

Metric	Xenetic Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.57M	$3.01B	$6.66B	$12.19B
Dividend Yield	N/A	1.78%	2.68%	5.89%
P/E Ratio	-2.39	18.83	25.35	24.07
Price / Sales	2.21	703.13	588.85	125.28
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	0.89	4.13	10.56	6.37
Net Income	-$2.68M	$64.45M	$3.56B	$337.11M
7 Day Performance	2.50%	0.55%	1.00%	-0.93%
1 Month Performance	-5.28%	0.26%	0.80%	0.65%
1 Year Performance	-26.03%	24.90%	31.01%	29.50%

Xenetic Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIO Xenetic Biosciences	0.3642 of 5 stars	$2.87 -1.0%	N/A	-7.6%	$6.57M	$2.98M	N/A	4	Gap Up
TAOX Synaptogenix	0.2901 of 5 stars	$3.39 -4.2%	N/A	N/A	$26.45M	$300K	N/A	4
AIXC Qualigen Therapeutics	0.1494 of 5 stars	$1.19 -7.8%	N/A	N/A	$26.10M	N/A	N/A	50
BCTX Briacell Therap	0.13 of 5 stars	$3.02 +1.0%	N/A	-89.8%	$26.01M	N/A	N/A	8	News Coverage
VTGN VistaGen Therapeutics	1.4301 of 5 stars	$0.66 +5.1%	$0.95 +42.9%	-68.2%	$25.94M	$1.27M	N/A	40	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIO) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenetic Biosciences (XBIO) Competitors

XBIO vs. TAOX, AIXC, BCTX, VTGN, and CPHI

How does Xenetic Biosciences compare to Synaptogenix?

Summary

How does Xenetic Biosciences compare to Qualigen Therapeutics?

Summary

How does Xenetic Biosciences compare to Briacell Therap?

Summary

How does Xenetic Biosciences compare to VistaGen Therapeutics?

Summary

How does Xenetic Biosciences compare to China Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenetic Biosciences (XBIO) Competitors

XBIO vs. TAOX, AIXC, BCTX, VTGN, and CPHI

How does Xenetic Biosciences compare to Synaptogenix?

Do analysts prefer XBIO or TAOX?

Which has more risk and volatility, XBIO or TAOX?

Do insiders & institutionals hold more shares of XBIO or TAOX?

Does the media refer more to XBIO or TAOX?

Is XBIO or TAOX more profitable?

Which has preferable earnings and valuation, XBIO or TAOX?

Summary

How does Xenetic Biosciences compare to Qualigen Therapeutics?

Do insiders & institutionals hold more shares of XBIO or AIXC?

Which has higher valuation & earnings, XBIO or AIXC?

Does the media refer more to XBIO or AIXC?

Is XBIO or AIXC more profitable?

Do analysts recommend XBIO or AIXC?

Which has more risk & volatility, XBIO or AIXC?

Summary

How does Xenetic Biosciences compare to Briacell Therap?

Do insiders and institutionals have more ownership in XBIO or BCTX?

Is XBIO or BCTX more profitable?

Which has more risk and volatility, XBIO or BCTX?

Do analysts recommend XBIO or BCTX?

Does the media refer more to XBIO or BCTX?

Which has stronger valuation & earnings, XBIO or BCTX?

Summary

How does Xenetic Biosciences compare to VistaGen Therapeutics?

Which has preferable valuation & earnings, VTGN or XBIO?

Which has more risk and volatility, VTGN or XBIO?

Is VTGN or XBIO more profitable?

Do insiders and institutionals hold more shares of VTGN or XBIO?

Does the media prefer VTGN or XBIO?

Do analysts recommend VTGN or XBIO?

Summary

How does Xenetic Biosciences compare to China Pharma?

Is CPHI or XBIO more profitable?

Does the media refer more to CPHI or XBIO?

Do institutionals & insiders believe in CPHI or XBIO?

Which has preferable valuation and earnings, CPHI or XBIO?

Which has more volatility & risk, CPHI or XBIO?

Do analysts rate CPHI or XBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO vs. The Competition

Xenetic Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools